Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# GB Sciences

The Future of Healing

## Sitemaps

- [XML Sitemap](https://www.gbsciences.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News Room](https://www.gbsciences.com/news-room/)
- [News from Washington D.C.](https://www.gbsciences.com/2018/01/26/washington-dc-news/) - Interesting news from Washington, D.C. this week, as a bi-partisan group of 54 members of Congress wrote in support of the Cole Memo, an Obama-era policy allowing states to determine their own course with cannabis enforcement. Click here to read the full article. DISCLAIMER REGARDING SITE CONTENT AND RELATED MATERIALS Please read these terms and
- [400% Sales Increase](https://www.gbsciences.com/2017/10/23/sales-increase/) - How did they balance being so funny and being such respected artists?” This question was recently posed by a visitor in reference
- [GB Sciences is "Happy"](https://www.gbsciences.com/2017/11/27/gb-sciences-happy/) - Mr. Kevin Kuethe has been appointed COO of GB Sciences. The company is happy, the plants are happy, the customers are happy, and the shareholders should definitely be happy. LAS VEGAS, Nov. 13, 2017 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that it has met the October gross revenue projection of $500K from the sale
- [Tissue Culture Propagation Breakthrough](https://www.gbsciences.com/2017/12/05/tissue-propagation/) - LAS VEGAS, December 5, 2017/PR Newswire/ -- GB Sciences, Inc. (OTCQB: GBLX) explains that 100% of the mother plants (a plant that in its vegetative state does not produce flowers but only branches and leaves) in their Las Vegas cultivation facility are now products of the GB Sciences tissue propagation initiative. In light of the
- [GB Sciences: Research is in our Corporate DNA](https://www.gbsciences.com/2017/12/11/research-in-our-dna/) - Click the window below to watch a short video: GB Sciences: Develops Extremely High THC Content Cannabis Strain With Maximized Terpene Levels To Increase Medical Benefits Three Complementary Operating Units Produce an Important Genetic Strain LAS VEGAS, December 13, 2017/PR Newswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is proud to announce its development of a
- [Dr. Small-Howard invited to Neuroscience Forum](https://www.gbsciences.com/2017/12/28/neuroscience_forum/) - LAS VEGAS, Dec. 26, 2017 /GB Sciences, Inc. (OTCQB: GBLX) will be represented on the Medical Cannabis in Neuroscience Panel at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco, on the 7th of January 2018. The event is held the day
- [GB Sciences Partners with Wellcana Group in Louisiana](https://www.gbsciences.com/2018/02/14/wellcana-louisiana/) - GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana GB Sciences Louisiana LLC. Will Operate One of Only Two Licenses Granted by the State of Louisiana under LSU Agricultural Center’s Medical Cannabis License LAS VEGAS, February 14, 2018/PR Newswire/--GB Sciences, Inc. (OTCQB: GBLX) and its wholly-owned subsidiary GB Sciences
- [CEO John Poss Interview](https://www.gbsciences.com/2018/02/19/john-poss-interview/) - CLICK HERE to read the interview at CEO/CFO Magazine Site Interview conducted by: Bud Wayne, Editorial Executive CEOCFO Magazine, Published – February 19, 2018 CEOCFO: Mr. Poss, you have a diverse background having serviced as CEO, CFO, COO and CTO in quite a number of different industries. What attracted you to GB Sciences and what
- [YouTube: Spinach Veins Replace Human Blood Vessels](https://www.gbsciences.com/2018/02/20/spinach-veins-replace-heart/) - Click here to watch the video on YouTube DISCLAIMER REGARDING SITE CONTENT AND RELATED MATERIALS Please read these terms and con­di­tions fully and care­fully. If you do not agree to be bound to each and every term and con­di­tion set forth herein, please exit the Site and do not access, read or oth­er­wise use infor­ma­tion pro­vided
- [New VP and General Counsel](https://www.gbsciences.com/2018/04/12/new-vp-general-counsel/) - GB Sciences Announces the Appointment of John B. Davis as Executive VP and General Counsel LAS VEGAS, April 12, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB:GBLX), a company that marries cutting edge cannabis cultivation and biopharmaceutical research and development, announced today that it has appointed John B. Davis as Executive Vice President, General Counsel -
- [Video: CEO John Poss on a "Small but Complex" Company](https://www.gbsciences.com/2018/04/13/poss-small-but-complex/) - Watch this short video of GBLX CEO John Poss as he fields questions from the web
- [Louisiana House backs expansion of medical cannabis program](https://www.gbsciences.com/2018/04/16/louisiana-medical-cannabis-2/) - This piece was originally published by the Associated Press and picked up in various publications. Click here to view the article there. Louisiana House backs expansion of medical cannabis program Louisiana lawmakers are moving to expand the state’s medical marijuana program, as the product nears availability within months. The House voted 60-39 Thursday to add
- [The State of Alaska: Boom or Bust?](https://www.gbsciences.com/2018/04/19/medical-cannabis-alaska/) - Alaska knows cannabis. Marijuana was growing in the shadow of the towering Matanuska Mountain Range when in 1975 the Supreme Court of Alaska ruled in Ravin v. State that the state constitution built in a resident’s right to privacy and that included the right to cultivate, possess and consume cannabis in the privacy of a
- [Video: What is a Cannabinoid?](https://www.gbsciences.com/2018/04/20/video-cannabinoid/) - Meredith Patterson is a nurse specializing in neurology. She writes about the brain and brain health at her blog - www.BrainStormmindfitness.com. DISCLAIMER REGARDING SITE CONTENT AND RELATED MATERIALS Please read these terms and con­di­tions fully and care­fully. If you do not agree to be bound to each and every term and con­di­tion set forth herein, please
- [CNN: Patients turn to pot over pills](https://www.gbsciences.com/2018/04/30/getting-off-opioids/) - This piece was originally published by CNN. Click here to view the article. By Nadia Kounang, CNN Watch Chief Medical Correspondent Dr. Sanjay Gupta's CNN Special Report "Weed 4: Pot vs. Pills" on Sunday, April 29, at 8 p.m. ET. (CNN)In 2016, opioids killed more Americans than breast cancer. The drug overdose epidemic has become
- [COLORADO](https://www.gbsciences.com/2018/05/08/medical-cannabis-colorado/) - Perhaps no other state has gained more notoriety as a legal cannabis state than the “Centennial State” so called because Colorado became a state in the year 1876, 100 years after the signing of our nation's Declaration of Independence. Colorado has become a Mecca for recreational cannabis users. Unlike most states that have legalized the
- [MISSOURI](https://www.gbsciences.com/2018/05/08/medical-cannabis-missouri/) - State House legislators of the “Show Me State” are tentatively testing the waters of legalized medical cannabis. HB 1554 was passed by a voice vote on April 23rd. The bill authorizes individuals 18 and over suffering from a terminal illness to legally purchases and use cannabis for medical purposes. The bill also legalizes the use
- [Cannabis: the Early Years and What They Teach Us](https://www.gbsciences.com/2018/05/10/cannabis-the-early-years/) - When I graduated from nursing school exactly 30 years ago, my brother presented me with a tombstone of an ancient medical text he found while combing the aisles of a used book store. It’s entitled “Library of Health” and it was published in 1916. The hefty tome has 1,774 pages and the front cover bears
- [VERMONT’S GARDENING EXPERIMENT](https://www.gbsciences.com/2018/07/11/medical-cannabis-vermont/) - Vermont is renowned for gardening expertise. Recently the Green State Gardener Store in Burlington, Vermont has seen a rush of business. July 1, 2018, Vermont’s legislation, Bill H511, took effect. It allows residents over the age of 21 to cultivate cannabis for recreational use. The number of allowed plants is lower than many states, the
- [GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))](https://www.gbsciences.com/2020/08/26/https-www-accesswire-com-603407-gb-sciences-files-provisional-patent-application-for-the-treatment-of-covid-19-related-acute-respiratory-distress-syndrome-ards-the-leading-cause-of-hospitalization-a/) - LAS VEGAS, NV / ACCESSWIRE / August 26, 2020 / GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of Cytokine Storm Syndromes (CSS), including acute respiratory distress syndrome (ARDS) in COVID-19 patients.
- [GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease](https://www.gbsciences.com/2020/08/14/https-www-accesswire-com-588219-gb-sciences-announces-issuance-of-us-patent-for-its-proprietary-cannabinoid-based-formulations-for-parkinsons-disease/) - LAS VEGAS, NV / ACCESSWIRE / May 4, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced today that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,653,640 entitled “Cannabinoid-Containing Complex Mixtures for the Treatment of Neurodegenerative Diseases” on May 19, 2020. The patent is assigned to GBS Global Biopharma (GBS), Inc.,
- [GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue](https://www.gbsciences.com/2019/03/13/gb-sciences-statement/) - LSU AgCenter issued the following statement on Friday, March 8th. LAS VEGAS, March 12, 2019/PR Newswire/-- GB Sciences, Inc. (OTCQB: GBLX) announces that the Louisiana State University Agricultural Center (LSU AgCenter) through William B. Richardson, Vice President for Agriculture, today issued the following statement on allegations made by the Commissioner of the Louisiana Department of
- [Statement From LSU AgCenter on False Allegations Made by LDAF Commissioner](https://www.gbsciences.com/2019/03/08/ag-center-statement/) - The Louisiana State University Agricultural Center (LSU AgCenter) through William B. Richardson, Vice President for Agriculture, today issued the following statement on allegations made by the Commissioner of the Louisiana Department of Agriculture and Forestry (LDAF) that LSU AgCenter and its public-private partner, GB Sciences Louisiana, are in violation of Louisiana’s medical marijuana law: “The
- [GB Sciences Team to Present at Digital Hollywood Forum](https://www.gbsciences.com/2018/10/11/digital-hollywood/) - Mr. Poss will speak on GB Sciences’ collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids. LAS VEGAS, October 10, 2018/PR Newswire/ — GB Sciences, Inc. (OTCQB: GBLX) announces that CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard will be featured on panels at the Digital
- [Nine Pharmacies to Serve Louisiana](https://www.gbsciences.com/2018/08/23/louisiana-pharmacies/) - In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program. BATON ROUGE, August 23, 2018/PR Newswire/ — GB Sciences, Inc. (OTCQB:GBLX) With the first cannabis crop now in production at their high-tech 36,000 square-foot grow facility in Baton Rouge, teams from GB Sciences and
- [GB Sciences Strengthens Compliance Program](https://www.gbsciences.com/2018/07/31/compliance-program/) - GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance he new Chief Compliance Officer Program and the SCORE App lay a solid compliance foundation to support GB Sciences’ rapidly maturing expansion plans. LAS VEGAS, July 31, 2018 – GB Sciences, Inc (OTCQB:GBLX) has contracted Adherence Compliance, a leading
- [First Quarter Revenue](https://www.gbsciences.com/2018/08/15/2018-first-quarter-revenue/) - GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year For the three months that ended June 30, 2018, the Company reported revenue of $1,315,284 and gross profit of $734,719. This compares to revenue and gross profit of $69,100 and
- [GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain](https://www.gbsciences.com/2020/08/14/https-www-prnewswire-com-news-releases-gb-sciences-announces-the-sale-of-the-majority-interest-in-nevada-cultivation-operations-to-focus-on-its-first-two-cannabinoid-based-medical-compounds-for-park/) - LAS VEGAS, Dec. 5, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production operation. This transaction will significantly reduce the Company's operating expenses, generate near-term working capital, and provide ongoing cashflow to enable the Company
- [GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada](https://www.gbsciences.com/2020/08/14/https-www-accesswire-com-583942-gb-sciences-completes-and-achieves-statistical-significance-in-preclinical-study-of-its-proprietary-parkinsons-disease-cannabinoid-formulations-and-begins-mechanism-o/) - LAS VEGAS / ACCESSWIRE / April 6, 2020 / GB Sciences, Inc. (OTCQB:GBLX), is pleased to announce that the company's Canadian entity, GBS Global Biopharma, Inc. (GBS), signed an Amendment to their Agreement with the National Research Council of Canada (NRC). The NRC has demonstrated that the company's PD formulations were able to reduce behavioral
- [GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated](https://www.gbsciences.com/2025/03/13/heart-failure/) - Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure. LAS VEGAS, November 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed
- [Research Collaboration in Spain](https://www.gbsciences.com/2017/10/10/chat-app-line-begins-to-offer-services/) - How did they balance being so funny and being such respected artists?” This question was recently posed by a visitor in reference
- [GBScience Forms Science Advisory Board](https://www.gbsciences.com/2017/10/31/science-advisory-board/) - How did they balance being so funny and being such respected artists?” This question was recently posed by a visitor in reference
- [Scientific Advisory Board Expands](https://www.gbsciences.com/2018/01/25/dr-zoltan-mari/) - LAS VEGAS, January 25, 2018/PR Newswire/--GB Sciences, Inc. (OTCQB: GBLX) welcomes Dr. Zoltan Mari, Section Head of the Nevada Movement Disorders Program and Lee Pascal Parkinson's Disease Scholar at Cleveland Clinic Lou Ruvo Center for Brain Health and a Clinical Professor of Neurology at the University of Nevada, Las Vegas, to its recently relaunched Scientific
- [GB Sciences and Parkinson’s Disease](https://www.gbsciences.com/2018/04/10/parkinsons-human-trial/) - GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease LAS VEGAS, April 10, 2018/PR Newswire/--. GB Sciences, Inc. (OTCQB: GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson’s
- [Video: CEO John Poss on Jeff Sessions](https://www.gbsciences.com/2018/04/13/poss-interview/) - Watch this short video of GBLX CEO John Poss as he fields questions from the web
- [GB Seeks Minor Cannabinoids for Patient Studies](https://www.gbsciences.com/2018/04/18/cannabinoids-patient-study/) - GB Sciences Seeking Partners to Supply Minor Cannabinoids for Parkinson’s Disease Clinical Trial Exploratory IND is planned using GB Sciences’ proprietary mixtures of botanical compounds to provide the highest efficacy for patients LAS VEGAS, April XX, 2018/PR Newswire/--. GB Sciences, Inc. (OTCQB: GBLX), as previously reported, plans to file an Exploratory IND and perform a
- [Video: CEO John Poss talks CBD, Cura, Hemp](https://www.gbsciences.com/2018/05/15/poss-interview-cbd-cura/) - Watch this short video of GBLX CEO John Poss as he fields questions from the web
- [Video: CEO John Poss talks Rec vs. Science](https://www.gbsciences.com/2018/05/15/poss-interview-cbd-cura-2/) - Watch this short video of GBLX CEO John Poss as he fields questions from the web
- [Video: CEO John Poss talks European Trials](https://www.gbsciences.com/2018/05/15/european-trials/) - Watch this short video of GBLX CEO John Poss as he fields questions from the web
- [Radio Interview: John Poss on Bill Martinez Live](https://www.gbsciences.com/2018/06/21/radio-poss-martinez/) - Watch this short video of GBLX CEO John Poss as he fields questions from the web
- [Researchers Name GB Sciences in Top 10](https://www.gbsciences.com/2018/07/11/canada-research-project/) - GB Sciences One of Ten Companies Named in Important New Canadian Research Publication Corporate strategy dedicated to scientific medical research, a viable drug development pipeline and a strong Intellectual Properties Patent Portfolio are cited as the key differentiating factors. LAS VEGAS, July 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) was named as one of
- [Peer-Reviewed Article for American Heart Association](https://www.gbsciences.com/2018/08/02/american-heart-association/) - GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: “Cannabinoids, The Heart of the Matter” This pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research. LAS VEGAS, August 2, 2018/PR Newswire/-- GB Sciences, Inc. (OTCQB: GBLX) is pleased to
- [GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery](https://www.gbsciences.com/2018/09/19/greece-partnership/) - GB Sciences explores the therapeutic potential of the chemical diversity within different varieties of the cannabis plant to make better medicine for patients worldwide. LAS VEGAS, September 19, 2018/PR Newswire/-- GB Sciences, Inc. (OTCQB: GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens,
- [Catalent to Provide Parkinson's Therapy Delivery Systems](https://www.gbsciences.com/2018/09/28/catalent/) - GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson’s disease SWINDON, U.K., and LAS VEGAS, September 26, 2018-- GB Sciences, Inc. (OTCQB: GBLX) and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and
- [DEA Rescheduling Benefits GB Sciences](https://www.gbsciences.com/2018/10/02/dea-epidiolex/) - DEA rescheduling of Epidiolex to Schedule V establishes commercial viability for cannabis-based formulations LAS VEGAS, October 2, 2018--GB Sciences, Inc. (OTCQB: GBLX) has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration (DEA)’s decision to reschedule GW Pharmaceuticals’ Epidiolex, from Schedule I to Schedule V of the Controlled Substances Act (CSA).
- [GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated](https://www.gbsciences.com/2018/11/27/heart-failure-2/) - Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure. LAS VEGAS, November 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed
- [GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.](https://www.gbsciences.com/2019/03/19/gbs-global-biopharma/) - Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson’s Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS, March 19, 2019/PR Newswire/-- GB Sciences, Inc. (OTCQB: GBLX) LAS VEGAS, GB Sciences, Inc. (OTCQB: GBLX) today launched a global expansion strategy with the formation of GBS Global Biopharma Inc. (“GBS Global”), a cannabinoid
- [GB  Sciences Files New Provisional Patent](https://www.gbsciences.com/2018/06/27/new-patents-2/) - GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain GB Sciences’ novel therapeutic approach paves the way for the creation of precision medicines derived from the cannabis plant. LAS VEGAS, June 27, 2018/GlobeNewswire/-- GB Sciences, Inc. (OTCQB: GBLX) has filed a new
- [GB  Sciences Files New Patents](https://www.gbsciences.com/2018/06/26/new-patents/) - GB Sciences Files Patents for Heart Disease and Chronic, Immunological, and Neuropathic Pain The nonprovisional patent applications protect formulations for pain and heart disease therapies based on myrcene-containing complex mixtures. LAS VEGAS, June 25, 2018/PR Newswire/-- GB Sciences, Inc. (OTCQB: GBLX) has filed nonprovisional patent applications to protect its myrcene-containing complex mixtures (“MCCC”) for the
- [GB Sciences in Benzinga Piece](https://www.gbsciences.com/2019/03/26/benzinga/)
- [GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors](https://www.gbsciences.com/2019/10/31/gb-sciences-welcomes-esteemed-patent-and-intellectual-property-attorney-mr-edmond-defrank-to-its-board-of-directors/) - LAS VEGAS, October 31, 2019/PR Newswire/-- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat. Mr. DeFrank is an attorney in the cannabis sector with deep expertise in patents and intellectual property. Mr. DeFrank brings a host of skills
- [GB Sciences Announces Issuance of US Patent for Its Proprietary Pain Formulations for the 560 Billion Dollar Chronic Pain Treatment Market](https://www.gbsciences.com/2020/08/14/https-www-accesswire-com-598037-gb-sciences-announces-issuance-of-us-patent-for-its-proprietary-pain-formulations-for-the-560-billion-dollar-chronic-pain-treatment-market/) - LAS VEGAS, NV / ACCESSWIRE / July 20, 2020 / GB Sciences, Inc. (OTCQB:GBLX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,709,670 entitled "Myrcene-Containing Complex Mixtures Targeting TRPV1" on July 14, 2020. This US patent is assigned to GBS Global Biopharma (GBS), Inc., GB Sciences' Canadian entity.

## Pages

- [Home](https://www.gbsciences.com/) - THE FUTURE OF HEALING We are a dedicated plant-based research and biopharmaceutical drug development company. Our goal is to create patented formulations of plant-inspired, minimum essential mixtures for use as prescription medications. Learn MorePARKINSON’S DISEASE THERAPIESWe achieved statistically significant results in our Animal Proof-of-Concept Study, and the US Patent was issued in 2020. Our goal
- [News](https://www.gbsciences.com/news-2/)
- [Finance](https://www.gbsciences.com/finance/) - Gb Sciences, Inc. (OTCQB:GBLX) GB Sciences, Inc. (OTCQB:GBLX) is a data-driven drug development company that leverages machine learning & high-throughput biology to transform plant-inspired drug development targeting novel treatments for multi-billion-dollar biopharma markets. Our AI-Powered Drug Discovery Platform (PhAROS™) predicts novel, simple, plant-based mixtures to address unmet health needs. PhAROS™ leverages demonstrated healing from 12
- [Buy Lisinopril Online | Best Prices for Lisinopril](https://www.gbsciences.com/buy-lisinopril-online-best-prices-for-lisinopril/) - Buy Lisinopril online at the best prices. Manage high blood pressure and heart conditions effectively with our high-quality Lisinopril. Fast shipping available.
- [How to Buy Amoxicillin Online Safely and Effectively](https://www.gbsciences.com/how-to-buy-amoxicillin-online-safely-and-effectively/) - With the growth of online pharmacies, buying medications online has become a popular option for many people. Amoxicillin, a widely used antibiotic, is one such medication that can be purchased online.
- [Buy Azithromycin Online | Best Prices for Azithromycin](https://www.gbsciences.com/buy-azithromycin-online-best-prices-for-azithromycin/) - Buy Azithromycin online at the best prices. Treat bacterial infections effectively with our high-quality Azithromycin. Fast shipping available.
- [Buying Losartan Online: Your Guide to Safe and Informed Choices](https://www.gbsciences.com/buying-losartan-online-your-guide-to-safe-and-informed-choices/) - This article provides a deep dive into everything you should consider before buying Losartan from an online source, from identifying legitimate sellers to understanding the medication's role in managing health conditions.
- [Buying Finasteride Online: What You Need to Know](https://www.gbsciences.com/buying-finasteride-online-what-you-need-to-know/) - This comprehensive guide will help you navigate the process, offering insights into safety, legality, and best practices for buying Finasteride from online sources.
- [Buy Accutane Online | Best Prices for Isotretinoin](https://www.gbsciences.com/buy-accutane-online-best-prices-for-isotretinoin/) - Buy Accutane (Isotretinoin) online at the best prices. Treat severe acne effectively with our high-quality Accutane. Fast shipping available.
- [Buy Ivermectin Online: A Comprehensive Guide](https://www.gbsciences.com/buy-ivermectin-online-a-comprehensive-guide/) - This article aims to provide a detailed guide on buying Ivermectin online safely and effectively, highlighting essential considerations, potential risks, and benefits.
- [Buy Modafinil Online | Best Prices for Modafinil (Provigil)](https://www.gbsciences.com/buy-modafinil-online-best-prices-for-modafinil-provigil/) - Buy Modafinil online (Provigil) at the best prices. Improve your focus, concentration, and productivity with our high-quality Modafinil. Fast shipping available.
- [Contact](https://www.gbsciences.com/contact/) - WHAT CAN WE DO TOGETHER? Contact Us Notice: JavaScript is required for this content. GBSciences, Inc. 9205 W Russell Road Suite 240 Las Vegas NV 89148 866.721.0297 info@gbsciences.com Company Privacy Policy
- [Privacy Policy](https://www.gbsciences.com/privacy-policy/) - PRIVACY POLICYLast updated March 21, 2023This privacy notice for Gb Sciences Inc. ("Company," "we," "us," or "our"), describes how and why we might collect, store, use, and/or share ("process") your information when you use our services ("Services"), such as when you:Visit our website at https://www.gbsciences.com, or any website of ours that links to this privacy
- [Science](https://www.gbsciences.com/science-2/) - THE RATIONAL DESIGN OF MINIMUM ESSENTIAL MIXTURES Our Goal is to preserve the efficacy of plant-based medicines while reducing their complexity for standardization. Our Strategy is to combine our proprietary PhAROS Drug Discovery Platform and High Throughput Screening of Cell and Animal Models of Specific Disease Processes to Create Rationally-Designed, Minimum Essential Mixtures. Learn More
- [Tab - News Articles](https://www.gbsciences.com/tab-press-releases-duplicate-8346/) - 2023 2022 2021 2023 2022 2021
- [Tab - White Paper](https://www.gbsciences.com/tab-white-paper/) - 2023 2022 2021 2023 2022
- [Tab - Press Releases](https://www.gbsciences.com/tab-press-releases/) - 2023 2022 2021 2023 2022 2021
- [Research & Development](https://www.gbsciences.com/research-development/) - RESEARCH & DEVELOPMENT PARTNERS Our novel drug development pipeline was built through collaborations with top University researchers, industry leaders in novel delivery and manufacturing processes, and respected hospitals who care about their patients.Our intellectual property portfolio of complex therapeutic mixtures currently includes: 6 issued US patents and 3 issued international patents as well as 17
- [News](https://www.gbsciences.com/news/) - [vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][masonry_blog order_by=”date” order=”ASC”][/vc_column][/vc_row]
- [Investors](https://www.gbsciences.com/investors/) - [vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” full_width=”stretch_row” parallax=”content-moving” css=”.vc_custom_1512069349975{padding-top: 10px !important;padding-bottom: 10px !important;background: #eaeaea url(https://www.gbsciences.com/wp-content/uploads/2017/11/Lab_Pic.jpg?id=757) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column width=”1/4″ css=”.vc_custom_1510107442014{padding-left: 80px !important;background-color: #ffffff !important;border-radius: 4px !important;}”][vc_empty_space height=”10px”][vc_custom_heading text=”Investing in Research” font_container=”tag:h2|text_align:left|color:%2300a557″ use_theme_fonts=”yes”][vc_column_text css=”.vc_custom_1598451545948{background-color: #ffffff !important;}”]At GB Sciences, we have two equally important constituencies–the patients who need what we do,
- [Home](https://www.gbsciences.com/gb-sciences-2/) - [vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1565230561581{background: #ffffff url(https://www.gbsciences.com/wp-content/uploads/2017/12/GBSciences_Top_of_Site.jpg?id=1457) !important;}” z_index=”” background_color=”#ffffff”][vc_column][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”2/3″][vc_empty_space height=”50px”][vc_custom_heading text=”The Future of Healing” font_container=”tag:h1|text_align:right|color:%2300a557″ use_theme_fonts=”yes”][vc_empty_space height=”150px”][/vc_column_inner][vc_column_inner width=”1/3″][vc_empty_space height=”300px”][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” row_negative_margin=”disable_negative_margin” z_index=”” background_color=”#ffffff”][vc_column css=”.vc_custom_1565229337929{background-color: #ffffff !important;}”][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=”” background_color=”#e4ebf3″ css=”.vc_custom_1513362307962{padding-top: 10px !important;padding-bottom: 20px !important;border-radius: 5px !important;}”][vc_column_inner width=”2/3″
- [Home](https://www.gbsciences.com/gb-sciences/) - [vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” css=”.vc_custom_1513830584395{background-image: url(https://www.gbsciences.com/wp-content/uploads/2017/12/GBSciences_Top_of_Site.jpg?id=1457) !important;}” z_index=””][vc_column][vc_row_inner row_type=”row” type=”full_width” text_align=”left” css_animation=””][vc_column_inner width=”2/3″][vc_empty_space height=”50px”][vc_custom_heading text=”The Future of Healing” font_container=”tag:h1|text_align:right|color:%2300a557″ use_theme_fonts=”yes”][vc_empty_space height=”150px”][/vc_column_inner][vc_column_inner width=”1/3″][vc_empty_space height=”300px”][vc_column_text css=”.vc_custom_1518022947284{padding-right: 30px !important;padding-left: 30px !important;}”][/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” row_negative_margin=”disable_negative_margin” z_index=””][vc_column][vc_row_inner row_type=”row” type=”full_width” text_align=”left” background_color=”#e4ebf3″ css_animation=”” css=”.vc_custom_1513362307962{padding-top: 10px !important;padding-bottom: 20px !important;border-radius: 5px !important;}”][vc_column_inner width=”2/3″][vc_empty_space height=”10px”][vc_single_image

## Podcasts

- [Stock Day Media: Interview with Andrea Small-Howard of Gb Sciences](https://www.gbsciences.com/podcasts/stock-day-media-interview-with-andrea-small-howard-of-gb-sciences/) - Stock Day Media: Interview with Andrea Small-Howard of Gb Sciences
- [Cannabis Business Times: Beyond the Show with Dr. Andrea Small-Howard](https://www.gbsciences.com/podcasts/cannabis-business-times-beyond-the-show-with-dr-andrea-small-howard/) - Cannabis Business Times: Beyond the Show with Dr. Andrea Small-Howard
- [Terpenes and Testing: The Podcast with Andrea Small-Howard, Ph.D.](https://www.gbsciences.com/podcasts/test-podcast-3/) - Terpenes and Testing: The Podcast with Andrea Small-Howard, Ph.D.
- [IDC Podcast: Bringing Medicines to Market Faster Through Analytics & Machine Learning](https://www.gbsciences.com/podcasts/test-podcast/) - IDC Podcast: Bringing Medicines to Market Faster Through Analytics & Machine Learning
- [DocWire Podcast: Dr. Andrea Small-Howard, Gb Sciences, Talks Plant-Based Therapies for Parkinson's Disease](https://www.gbsciences.com/podcasts/test-podcast-2/) - DocWire Podcast: Dr. Andrea Small-Howard, Gb Sciences, Talks Plant-Based Therapies for Parkinson's Disease

## Media Room

- [GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug](https://www.gbsciences.com/media_room/gb-sciences-signs-licensing-deal-with-endopure-life-sciences-for-5-gross-sales-royalty-sponsorship-of-first-in-human-trial-for-their-cannabinoid-based-parkinsons-drug-2/)
- [The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions](https://www.gbsciences.com/media_room/the-booming-market-of-plant-based-pharmaceuticals/)
- [Gb Sciences’ Novel Parkinson’s Disease Medication is Featured on Worldwide Business with kathy ireland®](https://www.gbsciences.com/media_room/gb-sciences-novel-parkinsons-disease-medication-is-featured-on-worldwide-business-with-kathy-ireland/)
- [Gb Sciences' First-in-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study at the University of Lethbridge](https://www.gbsciences.com/media_room/gb-sciences-first-in-class-parkinsons-disease-therapy-successfully-completes-dose-response-study-at-the-university-of-lethbridge/)
- [GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China](https://www.gbsciences.com/media_room/gb-sciences-first-international-patent-protecting-its-proprietary-cannabinoid-based-formulations-for-parkinsons-disease-has-been-issued-in-china/)
- [Successful 2022 Milestones Support Value of Gb Sciences' AI-Enabled Drug Discovery Platform](https://www.gbsciences.com/media_room/successful-2022-milestones-support-value-of-gb-sciences-ai-enabled-drug-discovery-platform/)
- [The Future of Medicine: Plant-inspired, Minimum Essential Mixtures](https://www.gbsciences.com/media_room/the-future-of-medicine-plant-inspired-minimum-essential-mixtures/)
- [Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations](https://www.gbsciences.com/media_room/gb-sciences-addresses-growing-need-for-anxiety-and-depression-medications-with-non-psychedelic-kava-based-formulations/) - LAS VEGAS, December 12, 2022 (Newswire.com) - Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety and depression medications through the development of novel, kava-inspired formulations, which are mood altering but non-hallucinogenic. Recently, Gb Sciences received positive preclinical results supporting the efficacy of its proprietary kava-based formulas
- [Navigating the COVID-19 Pandemic: A Novel Cannabinoid-Based Treatment Strategy](https://www.gbsciences.com/media_room/gb-sciences-co-publishes-study-demonstrating-anti-inflammatory-properties-of-cannabis-ingredients/)
- [Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients](https://www.gbsciences.com/media_room/gb-sciences-co-publishes-study-demonstrating-anti-inflammatory-properties-of-cannabis-ingredients-2/)
- [TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit](https://www.gbsciences.com/media_room/today-gb-sciences-president-demonstrates-benefits-of-ai-enabled-drug-discovery-engine-for-novel-plant-inspired-pharmaceuticals-at-10th-annual-drug-discovery-strategic-summit-2/)
- [TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference](https://www.gbsciences.com/media_room/today-gb-sciences-president-demonstrates-effectiveness-of-simplified-therapeutic-mixtures-inspired-by-cannabis-plant-extracts-at-canna-pharma-2022-conference/)
- [TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit](https://www.gbsciences.com/media_room/today-gb-sciences-showcases-its-pharos-drug-discovery-platform-at-the-2nd-alcor-drug-discovery-platform-summit/)
- [Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study](https://www.gbsciences.com/media_room/gb-sciences-plant-based-formulations-designed-to-treat-anxiety-achieve-statistical-significance-in-animal-study/)
- [Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease](https://www.gbsciences.com/media_room/gb-sciences-co-publishes-study-demonstrating-efficacy-of-its-proprietary-cannabinoid-mixtures-for-the-treatment-of-parkinsons-disease/)
- [TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article](https://www.gbsciences.com/media_room/today-gb-sciences-describes-drug-development-progress-in-pharmas-almanac-journal-article/)
- [Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™](https://www.gbsciences.com/media_room/gb-sciences-is-leading-digital-transformation-in-biopharma-industry-through-its-novel-ai-accelerated-drug-discovery-platform-pharos/)
- [TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit](https://www.gbsciences.com/media_room/today-gb-sciences-president-and-chief-science-officer-presents-keynote-address-on-cannabinoid-containing-formulations-for-parkinsons-disease-at-2022-neuroforum-summit/)
- [TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference](https://www.gbsciences.com/media_room/today-gb-sciences-novel-plant-inspired-pain-medications-featured-at-smis-22nd-annual-pain-therapeutics-conference/)
- [FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies](https://www.gbsciences.com/media_room/fhi-clinical-to-write-clinical-trial-protocol-for-development-of-gb-sciences-covid-19-related-anti-inflammatory-therapies/)
- [Gb Sciences to Begin Dosage Study for Its Novel Parkinson's Disease Formulations at the University of Lethbridge](https://www.gbsciences.com/media_room/gb-sciences-to-begin-dosage-study-for-its-novel-parkinsons-disease-formulations-at-the-university-of-lethbridge/)
- [Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article](https://www.gbsciences.com/media_room/gb-sciences-nanoparticle-encapsulation-technology-improves-the-efficacy-of-terpenes-for-use-in-our-chronic-pain-formulations-as-demonstrated-in-new-research-article/)
- [Gb Sciences Issues Shareholder Letter](https://www.gbsciences.com/media_room/gb-sciences-issues-shareholder-letter/)
- [Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment](https://www.gbsciences.com/media_room/gb-sciences-and-michigan-state-university-researchers-have-identified-the-complicated-truth-behind-the-opportunity-for-an-effective-cannabinoid-based-coronavirus-treatment/)
- [Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis](https://www.gbsciences.com/media_room/gb-sciences-granted-u-s-patent-for-cannabinoid-containing-treatment-for-advanced-heart-disease-trpv1-receptor-associated-hearing-loss-and-urinary-cystitis/)
- [Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility](https://www.gbsciences.com/media_room/gb-sciences-completes-8-million-sale-of-las-vegas-cannabis-facility/)
- [Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives](https://www.gbsciences.com/media_room/gb-sciences-targets-covid-19-treatment-as-omicron-variant-arrives/)
- [Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships](https://www.gbsciences.com/media_room/gb-sciences-accelerates-drug-development-via-innovative-biopharma-technology-and-strategic-partnerships/)
- [Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety](https://www.gbsciences.com/media_room/gb-sciences-starts-preclinical-study-for-plant-based-formulas-to-treat-depression-and-anxiety/)
- [Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation](https://www.gbsciences.com/media_room/gb-sciences-achieves-positive-proof-of-concept-results-for-their-cytokine-release-syndrome-therapies-designed-to-suppress-covid-related-hyperinflammation/)
- [Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference](https://www.gbsciences.com/media_room/gb-sciences-presenting-covid-related-cytokine-release-syndrome-results-at-h-c-wainwrights-23rd-annual-global-investment-conference/)
- [Potential use for chronic pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) nanoparticles enhance the effects of Cannabis-Based terpenes on calcium influx in TRPV1-Expressing cells](https://www.gbsciences.com/media_room/potential-use-for-chronic-pain-polyethylene-glycol-polylactic-co-glycolic-acid-nanoparticles-enhance-the-effects-of-cannabis-based-terpenes-on-calcium-influx-in-trpv1-expressing-cells/)
- [Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures](https://www.gbsciences.com/media_room/unlocking-the-therapeutic-potential-of-plant-inspired-minimum-essential-mixtures/)
- [Exploring the Natural Pharmacopeia and Incubating a Biotech Company](https://www.gbsciences.com/media_room/exploring-the-natural-pharmacopeia-and-incubating-a-biotech-company/)
- [University of Lethbridge researching possible Parkinson’s disease treatments](https://www.gbsciences.com/media_room/university-of-lethbridge-researching-possible-parkinsons-disease-treatments/)
- [Harnessing the Power of Cannabis-Derived Ingredients for the Prescription Drug Market](https://www.gbsciences.com/media_room/harnessing-the-power-of-cannabis-derived-ingredients-for-the-prescription-drug-market/)
- [Drug discovery company works with ethnobotanists and data scientists](https://www.gbsciences.com/media_room/drug-discovery-company-works-with-ethnobotanists-and-data-scientists/)
- [‘This is Going to Change the Way People Think About Medicine’: Q&A with Dr. Andrea Small-Howard](https://www.gbsciences.com/media_room/this-is-going-to-change-the-way-people-think-about-medicine-qa-with-dr-andrea-small-howard/)
- [Medicine in motion: Opportunities, challenges and data analytics-based solutions for traditional medicine integration into western medical practice](https://www.gbsciences.com/media_room/medicine-in-motion-opportunities-challenges-and-data-analytics-based-solutions-for-traditional-medicine-integration-into-western-medical-practice/)
- [Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform](https://www.gbsciences.com/media_room/gb-sciences-identifies-novel-cannabis-inspired-mixtures-as-anti-inflammatory-therapies-based-on-proprietary-ai-enabled-drug-discovery-platform/)
- [White Paper - Anti-Inflammatory Therapeutics](https://www.gbsciences.com/media_room/white-paper-anti-inflammatory-therapeutics/)
- [White Paper - Parkinson's Disease](https://www.gbsciences.com/media_room/today-gb-sciences-president-demonstrates-benefits-of-ai-enabled-drug-discovery-engine-for-novel-plant-inspired-pharmaceuticals-at-10th-annual-drug-discovery-strategic-summit/)
- [White Paper - Chronic Pain](https://www.gbsciences.com/media_room/white-paper-chronic-pain/)

## Articles

- [GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug](https://www.gbsciences.com/article/gb-sciences-signs-licensing-deal-with-endopure-life-sciences-for-5-gross-sales-royalty-sponsorship-of-first-in-human-trial-for-their-cannabinoid-based-parkinsons-drug/) - Press Release Oct 15, 2024 07:00 EDT As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials, which help to advance GB Sciences’ cannabinoid-based products globally. LAS VEGAS, October 15, 2024 (Newswire.com) - GB Sciences, Inc. (OTCQB:GBLX), a leading data-driven, plant-inspired biopharmaceutical development company, has signed an exclusive licensing
- [Stocks Today: The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions](https://www.gbsciences.com/article/stocks-today-the-booming-market-of-plant-based-pharmaceuticals-for-neurological-conditions/) - The Booming Market of Plant-Based Pharmaceuticals for Neurological Conditions
- [Science Direct: Uncovering the metabolite complexity and variability of cultivated hemp](https://www.gbsciences.com/article/uncovering-the-metabolite-complexity-and-variability-of-cultivated-hemp-cannabis-sativa-l-a-first-phytochemical-diversity-mapping-in-greece/) - Uncovering the metabolite complexity and variability of cultivated hemp (Cannabis sativa L.): A first phytochemical diversity mapping in Greece
- [Future Healthcare Today](https://www.gbsciences.com/article/future-healthcare-today/) - Navigating the COVID-19 Pandemic: A Novel Cannabinoid-Based Treatment Strategy
- [Andrea Small-Howard, Ph.D.](https://www.gbsciences.com/article/5534/) - Pharma's Almanac: Exploring the Natural Pharmacopeia and Incubating a Biotech Company
- [C. Jansen](https://www.gbsciences.com/article/5535/) - Medicine in motion: Opportunities, challenges and data analytics-based solutions for traditional medicine integration into western medical practice
- [Cannabis Business Times](https://www.gbsciences.com/article/cannabis-business-times/) - Cannabis Business Times: ‘This is Going to Change the Way People Think About Medicine’: Q&A with Dr. Andrea Small-Howard
- [TechRepublic](https://www.gbsciences.com/article/techrepublic/) - TechRepublic: Drug discovery company works with ethnobotanists and data scientists
- [Terpenes & Testing](https://www.gbsciences.com/article/terpenes-testing/) - Terpenes & Testing: Harnessing the Power of Cannabis-Derived Ingredients for the Prescription Drug Market
- [Mazen M.El-Hammadi](https://www.gbsciences.com/article/mazen-m-el-hammadi/) - Potential use for chronic pain: Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) nanoparticles enhance the effects of Cannabis-Based terpenes on calcium influx in TRPV1-Expressing cells
- [Calgary CTV News](https://www.gbsciences.com/article/calgary-ctv-news/) - University of Lethbridge researching possible Parkinson’s disease treatments
- [Pharma's Almanac: Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures](https://www.gbsciences.com/article/pharmas-almanac-unlocking-the-therapeutic-potential-of-plant-inspired-minimum-essential-mixtures/) - Pharma's Almanac: Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures

## Categories

- [Science](https://www.gbsciences.com/category/science/)
- [Medical](https://www.gbsciences.com/category/medical/)
- [Cultivation](https://www.gbsciences.com/category/cultivation/)
- [Partners](https://www.gbsciences.com/category/partners/)
- [Extraction](https://www.gbsciences.com/category/extraction/)
- [Press Release](https://www.gbsciences.com/category/media-room/press-release/)
- [Breaking News](https://www.gbsciences.com/category/breaking-news/)
- [Media](https://www.gbsciences.com/category/media/)
- [State of the States](https://www.gbsciences.com/category/state-of-the-states/)
- [GB Sciences](https://www.gbsciences.com/category/gb-sciences/)
- [Guest Blogger](https://www.gbsciences.com/category/guest-blogger/)
- [CEO John Poss](https://www.gbsciences.com/category/ceo-john-poss/)
- [Featured Home](https://www.gbsciences.com/category/featured-home/)
- [Media Room](https://www.gbsciences.com/category/media-room/)
- [News Article](https://www.gbsciences.com/category/media-room/news-article/)
- [White Paper](https://www.gbsciences.com/category/media-room/white-paper/)

## Tags

- [innovation](https://www.gbsciences.com/tag/innovation/)
- [science](https://www.gbsciences.com/tag/science/)
- [technology](https://www.gbsciences.com/tag/technology/)
- [trends](https://www.gbsciences.com/tag/trends/)
- [wasington d.c.](https://www.gbsciences.com/tag/wasington-d-c/)